594 related articles for article (PubMed ID: 16403774)
1. The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.
Meier JJ; Gethmann A; Nauck MA; Götze O; Schmitz F; Deacon CF; Gallwitz B; Schmidt WE; Holst JJ
Am J Physiol Endocrinol Metab; 2006 Jun; 290(6):E1118-23. PubMed ID: 16403774
[TBL] [Abstract][Full Text] [Related]
2. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans.
Meier JJ; Nauck MA; Pott A; Heinze K; Goetze O; Bulut K; Schmidt WE; Gallwitz B; Holst JJ
Gastroenterology; 2006 Jan; 130(1):44-54. PubMed ID: 16401467
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men.
Schirra J; Kuwert P; Wank U; Leicht P; Arnold R; Göke B; Katschinski M
Proc Assoc Am Physicians; 1997 Jan; 109(1):84-97. PubMed ID: 9010920
[TBL] [Abstract][Full Text] [Related]
5. Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia.
Deane AM; Chapman MJ; Fraser RJ; Summers MJ; Zaknic AV; Storey JP; Jones KL; Rayner CK; Horowitz M
Crit Care Med; 2010 May; 38(5):1261-9. PubMed ID: 20228679
[TBL] [Abstract][Full Text] [Related]
6. The antagonistic metabolite of GLP-1, GLP-1 (9-36)amide, does not influence gastric emptying and hunger sensations in man.
Nagell CF; Pedersen JF; Holst JJ
Scand J Gastroenterol; 2007 Jan; 42(1):28-33. PubMed ID: 17190759
[TBL] [Abstract][Full Text] [Related]
7. Gastric inhibitory polypeptide does not inhibit gastric emptying in humans.
Meier JJ; Goetze O; Anstipp J; Hagemann D; Holst JJ; Schmidt WE; Gallwitz B; Nauck MA
Am J Physiol Endocrinol Metab; 2004 Apr; 286(4):E621-5. PubMed ID: 14678954
[TBL] [Abstract][Full Text] [Related]
8. Effects of the phases of the menstrual cycle on gastric emptying, glycemia, plasma GLP-1 and insulin, and energy intake in healthy lean women.
Brennan IM; Feltrin KL; Nair NS; Hausken T; Little TJ; Gentilcore D; Wishart JM; Jones KL; Horowitz M; Feinle-Bisset C
Am J Physiol Gastrointest Liver Physiol; 2009 Sep; 297(3):G602-10. PubMed ID: 19556358
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide 2 inhibits ghrelin secretion in humans.
Banasch M; Bulut K; Hagemann D; Schrader H; Holst JJ; Schmidt WE; Meier JJ
Regul Pept; 2006 Dec; 137(3):173-8. PubMed ID: 16928403
[TBL] [Abstract][Full Text] [Related]
10. The effects of fiber enrichment of pasta and fat content on gastric emptying, GLP-1, glucose, and insulin responses to a meal.
Frost GS; Brynes AE; Dhillo WS; Bloom SR; McBurney MI
Eur J Clin Nutr; 2003 Feb; 57(2):293-8. PubMed ID: 12571662
[TBL] [Abstract][Full Text] [Related]
11. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.
Meier JJ; Kemmeries G; Holst JJ; Nauck MA
Diabetes; 2005 Jul; 54(7):2212-8. PubMed ID: 15983224
[TBL] [Abstract][Full Text] [Related]
12. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.
Nauck MA; Walberg J; Vethacke A; El-Ouaghlidi A; Senkal M; Holst JJ; Gallwitz B; Schmidt WE; Schmiegel W
Regul Pept; 2004 Apr; 118(1-2):89-97. PubMed ID: 14759561
[TBL] [Abstract][Full Text] [Related]
13. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans.
Vella A; Shah P; Reed AS; Adkins AS; Basu R; Rizza RA
Diabetologia; 2002 Oct; 45(10):1410-5. PubMed ID: 12378382
[TBL] [Abstract][Full Text] [Related]
14. Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects.
Chaikomin R; Doran S; Jones KL; Feinle-Bisset C; O'Donovan D; Rayner CK; Horowitz M
Am J Physiol Endocrinol Metab; 2005 Sep; 289(3):E504-7. PubMed ID: 15886226
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
Nauck MA; Niedereichholz U; Ettler R; Holst JJ; Orskov C; Ritzel R; Schmiegel WH
Am J Physiol; 1997 Nov; 273(5):E981-8. PubMed ID: 9374685
[TBL] [Abstract][Full Text] [Related]
16. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses.
Little TJ; Pilichiewicz AN; Russo A; Phillips L; Jones KL; Nauck MA; Wishart J; Horowitz M; Feinle-Bisset C
J Clin Endocrinol Metab; 2006 May; 91(5):1916-23. PubMed ID: 16492694
[TBL] [Abstract][Full Text] [Related]
17. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
Rosenstock J; Foley JE; Rendell M; Landin-Olsson M; Holst JJ; Deacon CF; Rochotte E; Baron MA
Diabetes Care; 2008 Jan; 31(1):30-5. PubMed ID: 17947341
[TBL] [Abstract][Full Text] [Related]
18. Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying.
Nicolaus M; Brödl J; Linke R; Woerle HJ; Göke B; Schirra J
J Clin Endocrinol Metab; 2011 Jan; 96(1):229-36. PubMed ID: 21047924
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes.
Nauck MA; Holst JJ; Willms B; Schmiegel W
Exp Clin Endocrinol Diabetes; 1997; 105(4):187-95. PubMed ID: 9285204
[TBL] [Abstract][Full Text] [Related]
20. No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects.
Lerche S; Soendergaard L; Rungby J; Moeller N; Holst JJ; Schmitz OE; Brock B
Clin Endocrinol (Oxf); 2009 Oct; 71(4):500-6. PubMed ID: 19094067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
